Anti-CLDN18.2 Monoclonal Antibody ZL-1211

Preferred Label : Anti-CLDN18.2 Monoclonal Antibody ZL-1211;

NCIt synonyms : Anti-Claudin18.2 Monoclonal Antibody ZL-1211;

NCIt definition : An engineered monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 monoclonal antibody ZL-1211 specifically targets and binds to CLDN18.2 expressed on tumor cells. The binding induces antibody-dependent cellular cytotoxicity (ADCC) and activates innate and adaptive immunity. This kills and inhibits proliferation of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.;

Molecule name : ZL 1211; ZL-1211;

NCI Metathesaurus CUI : CL1905176;

Détails

Origin ID

C191757;

UMLS CUI

C5784712;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Claudin-18 Isoform A2 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients